Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Patrick H. Higgins is a member in the intellectual property group at the law firm of Eckert Seamans Cherin & Mellott in Philadelphia.
More GEN Content From This Contributor:
- GEN Exclusives: Market Exclusivity—Paramount in Evaluating Target Companies